In8Bio (INAB) Share-based Compensation (2020 - 2026)

In8Bio has disclosed Share-based Compensation across 7 years of filings, most recently posting $1.6 million for Q2 2026.

• In Q2 2026, Share-based Compensation rose 65.44% year-over-year to $1.6 million; the TTM figure through Jun 2026 stood at $1.6 million (down 54.24% YoY), while the FY2025 annual figure was $3.2 million, down 36.22% from the prior year.
• Share-based Compensation came in at $1.6 million for Q2 2026 at In8Bio, up from $988267.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $14.9 million in Q1 2025 to a low of $421000.0 in Q4 2022.
• Average Share-based Compensation over 5 years is $4.4 million, with a median of $3.2 million recorded in 2022.
• Year-over-year, Share-based Compensation surged 734.68% in 2022 and sank 93.38% in 2026.
• Over 5 years, Share-based Compensation stood at $421000.0 in 2022, then surged by 197.39% to $1.3 million in 2023, then tumbled by 34.11% to $825000.0 in 2024, then fell by 13.82% to $711000.0 in 2025, then jumped by 122.22% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $1.6 million in Q2 2026, $988267.0 in Q1 2026, and $711000.0 in Q4 2025.